Mifamurtide Sodium Hydrate

米伐木肽钠

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameMifamurtide Sodium Hydrate
Drug Alias Namemifamurtida米法牟肽mifamurtidum米法莫肽米伐木肽 +[14
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMacrophages stimulants
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsOsteosarcoma +[4
Global Approved IndicationsOsteosarcoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2009/03/06
Country/TerritoryUnited StatesNorwayUnited Kingdom +[4
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTakeda France Sas
Active IndicationsOsteosarcoma
Inactive IndicationsSolid tumoursColorectal NeoplasmsHIV Infections

Other Information

ATC CodeL03AX15
Related LinksWikipediaKEGG